IP Library Granted Patent US 7,311,904
Granted Patent B2
US 7,311,904 · App. 10/074,976 · Granted Dec 25, 2007

Tissue matrices comprising placental stem cells, and methods of making the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,311,904
App. No.
10/074,976
Granted
Dec 25, 2007
Kind
B2
Abstract

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Claims (5)

1. A tissue matrix comprising placental stem cells, wherein the placental stem cells are CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , and SH4 + ; wherein said placental stem cells are additionally OCT-4 + , SSEA3 − or SSEA4 − ; and wherein said tissue matrix is made by a method comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood.

2. A method of making a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, wherein said placental stem cells are CD34 − , SSEA3 − , SSEA4 − , and OCT-4 + .

3. A method of making a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, wherein said placental stem cells are CD10 + , CD29 + , CD34 − , CD44 − , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , and SH4 + ; and wherein said placental stem cells are additionally OCT-4 + , SSEA3 − or SSEA4 − .

4. A decellularized or synthetic tissue matrix comprising human placental stem cells, wherein the placental stem cells are CD34 − , SSEA3 − , SSEA4 − , and OCT-4 + .

5. A decellularized or synthetic tissue matrix comprising human placental stem cells, wherein the placental stem cells are CD34 − , CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , and SH4 + ; and wherein said placental stem cells are additionally OCT-4 + , SSEA3 − or SSEA4 − .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2003
From: HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 013743/0637 →